Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Spring Bank Pharmaceuticals Top-Line Results of Second Cohort (50mg) of Part A of Phase 2 ACHIEVE Trial  (Replay)
    Thursday, November 16, 2017 8:00 am EST
Toggle Summary Spring Bank Pharmaceuticals Receives Allowance for US Patent
Milford, MA, November 15, 2011 – Spring Bank Pharmaceuticals, Inc., announces that the United States Patent and Trademark Office has allowed the U.S. patent 11/637,520 (“the patent”) titled “Nucleotide and Oligonucleotide Prodrugs”, co-inventors Iyer and Padmanabhan.
Toggle Summary Spring Bank Pharmaceuticals Presents Study Results for Novel Anti-Viral Pharmaceuticals from its Small Molecule Nucleic Acid Hybrid technology platform
Milford, MA – February 2010 – Spring Bank Pharmaceuticals, Inc., a  biopharmaceutical company capitalizing on its proprietary Small Molecule Nucleic Acid  Hybrid technology platform announced today that it will present four (4) posters on it  breakthrough products for the treatment